Literature DB >> 31873980

Mistaking the Trees for the Forest?

Garth W Strohbehn1, Christopher K Daugherty1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31873980      PMCID： PMC7160407          DOI： 10.1634/theoncologist.2019-0801

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

1.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Authors:  Susanne Saussele; Johan Richter; Joelle Guilhot; Franz X Gruber; Henrik Hjorth-Hansen; Antonio Almeida; Jeroen J W M Janssen; Jiri Mayer; Perttu Koskenvesa; Panayiotis Panayiotidis; Ulla Olsson-Strömberg; Joaquin Martinez-Lopez; Philippe Rousselot; Hanne Vestergaard; Hans Ehrencrona; Veli Kairisto; Katerina Machová Poláková; Martin C Müller; Satu Mustjoki; Marc G Berger; Alice Fabarius; Wolf-Karsten Hofmann; Andreas Hochhaus; Markus Pfirrmann; Francois-Xavier Mahon
Journal:  Lancet Oncol       Date:  2018-05-04       Impact factor: 41.316

2.  Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

Authors:  Kathryn E Flynn; Judith M Myers; Anita D'Souza; Charles A Schiffer; James E Thompson; Ehab Atallah
Journal:  Oncologist       Date:  2019-04-03

3.  Understanding choice: why physicians should learn prospect theory.

Authors:  Amol A Verma; Fahad Razak; Allan S Detsky
Journal:  JAMA       Date:  2014-02-12       Impact factor: 56.272

4.  Applying community-based participatory research principles and approaches in clinical trials: forging a new model for cancer clinical research.

Authors:  Sarena D Seifer; Margo Michaels; Stacy Collins
Journal:  Prog Community Health Partnersh       Date:  2010

5.  Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates.

Authors:  Mira L Katz; Laura E Archer; Jeffrey M Peppercorn; Sandra Kereakoglow; Deborah E Collyar; Harold J Burstein; Richard L Schilsky; Ann H Partridge
Journal:  Cancer       Date:  2012-03-05       Impact factor: 6.860

6.  De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Authors:  Richard E Clark; Fotios Polydoros; Jane F Apperley; Dragana Milojkovic; Katherine Rothwell; Christopher Pocock; Jennifer Byrne; Hugues de Lavallade; Wendy Osborne; Lisa Robinson; Stephen G O'Brien; Lucy Read; Letizia Foroni; Mhairi Copland
Journal:  Lancet Haematol       Date:  2019-06-12       Impact factor: 18.959
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.